A phase 1 study of adoptive immunotherapy using autologous RNF43 peptide pulse dendritic cells and RNF43 peptide specifically activated lymphocytes in patients with advanced solid tumors
Phase 1
- Conditions
- advanced solid tumors which already have finished available standard therapies.
- Registration Number
- JPRN-UMIN000003945
- Lead Sponsor
- Kyushu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with severe pre-exiting diseases :autoimmune diseases, an active infectious diseases, cardiovascular disorders, respiratory disorders, renal dysfunction, immunodeficiency, and hematological disorders. 2.Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner 3.No active brain metastases. 4.Patients who should receive systemic administration of steroid or immunosuppressive agents. 5.Inappropriate for study entry judged by an attending physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety
- Secondary Outcome Measures
Name Time Method clinical efficacy and immunologic monitoring